Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions ...

Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” ...